GB202006079D0 - New composition - Google Patents

New composition

Info

Publication number
GB202006079D0
GB202006079D0 GBGB2006079.4A GB202006079A GB202006079D0 GB 202006079 D0 GB202006079 D0 GB 202006079D0 GB 202006079 A GB202006079 A GB 202006079A GB 202006079 D0 GB202006079 D0 GB 202006079D0
Authority
GB
United Kingdom
Prior art keywords
new composition
composition
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2006079.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Priority to GBGB2006079.4A priority Critical patent/GB202006079D0/en
Publication of GB202006079D0 publication Critical patent/GB202006079D0/en
Priority to JP2022540540A priority patent/JP7387903B2/ja
Priority to AU2021260923A priority patent/AU2021260923B2/en
Priority to KR1020227039916A priority patent/KR20230005220A/ko
Priority to PL21724012.6T priority patent/PL4138790T3/pl
Priority to EP24154507.8A priority patent/EP4389212A3/en
Priority to MX2022013070A priority patent/MX2022013070A/es
Priority to LTEPPCT/GB2021/050994T priority patent/LT4138790T/lt
Priority to DK21724012.6T priority patent/DK4138790T3/da
Priority to PT217240126T priority patent/PT4138790T/pt
Priority to EP21724012.6A priority patent/EP4138790B1/en
Priority to BR112022021511A priority patent/BR112022021511A2/pt
Priority to CA3180646A priority patent/CA3180646A1/en
Priority to CN202180042663.8A priority patent/CN115697309A/zh
Priority to SI202130130T priority patent/SI4138790T1/sl
Priority to IL297373A priority patent/IL297373B1/en
Priority to ES21724012T priority patent/ES2976885T3/es
Priority to PCT/GB2021/050994 priority patent/WO2021214488A1/en
Priority to US17/696,984 priority patent/US11844868B2/en
Priority to ZA2022/11460A priority patent/ZA202211460B/en
Priority to US18/491,946 priority patent/US12605341B2/en
Priority to JP2023194557A priority patent/JP2024020417A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2006079.4A 2020-04-24 2020-04-24 New composition Ceased GB202006079D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition
PCT/GB2021/050994 WO2021214488A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
EP21724012.6A EP4138790B1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
CA3180646A CA3180646A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
KR1020227039916A KR20230005220A (ko) 2020-04-24 2021-04-23 경구 투여용 신규 건조 분말 조성물
PL21724012.6T PL4138790T3 (pl) 2020-04-24 2021-04-23 Nowa kompozycja suchego proszku do podawania doustnego
EP24154507.8A EP4389212A3 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
MX2022013070A MX2022013070A (es) 2020-04-24 2021-04-23 Nueva composición en polvo seco para administración peroral.
LTEPPCT/GB2021/050994T LT4138790T (lt) 2020-04-24 2021-04-23 Naujoji sausų miltelių sudėtis, skirta peroraliniam vartojimui
DK21724012.6T DK4138790T3 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
PT217240126T PT4138790T (pt) 2020-04-24 2021-04-23 Nova composição de pó seco para administração peroral
JP2022540540A JP7387903B2 (ja) 2020-04-24 2021-04-23 経口投与用の新しい乾燥粉末組成物
BR112022021511A BR112022021511A2 (pt) 2020-04-24 2021-04-23 Composição de pó seco para administração peroral
AU2021260923A AU2021260923B2 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
CN202180042663.8A CN115697309A (zh) 2020-04-24 2021-04-23 经口施用的新型干粉组合物
SI202130130T SI4138790T1 (sl) 2020-04-24 2021-04-23 Nov sestavek suhega praška peroralno dajanje
IL297373A IL297373B1 (en) 2020-04-24 2021-04-23 A new dry powder preparation for oral administration
ES21724012T ES2976885T3 (es) 2020-04-24 2021-04-23 Nueva composición en polvo seco para administración peroral
US17/696,984 US11844868B2 (en) 2020-04-24 2022-03-17 Dry powder composition for peroral administration
ZA2022/11460A ZA202211460B (en) 2020-04-24 2022-10-19 New dry powder composition for peroral administration
US18/491,946 US12605341B2 (en) 2020-04-24 2023-10-23 Dry powder composition for peroral administration
JP2023194557A JP2024020417A (ja) 2020-04-24 2023-11-15 経口投与用の新しい乾燥粉末組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition

Publications (1)

Publication Number Publication Date
GB202006079D0 true GB202006079D0 (en) 2020-06-10

Family

ID=71080269

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2006079.4A Ceased GB202006079D0 (en) 2020-04-24 2020-04-24 New composition

Country Status (19)

Country Link
US (2) US11844868B2 (https=)
EP (2) EP4389212A3 (https=)
JP (2) JP7387903B2 (https=)
KR (1) KR20230005220A (https=)
CN (1) CN115697309A (https=)
AU (1) AU2021260923B2 (https=)
BR (1) BR112022021511A2 (https=)
CA (1) CA3180646A1 (https=)
DK (1) DK4138790T3 (https=)
ES (1) ES2976885T3 (https=)
GB (1) GB202006079D0 (https=)
IL (1) IL297373B1 (https=)
LT (1) LT4138790T (https=)
MX (1) MX2022013070A (https=)
PL (1) PL4138790T3 (https=)
PT (1) PT4138790T (https=)
SI (1) SI4138790T1 (https=)
WO (1) WO2021214488A1 (https=)
ZA (1) ZA202211460B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
JP2008502699A (ja) 2004-06-14 2008-01-31 セプラコール・インコーポレイテッド 肺疾患治療方法、及びそのための組成物
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20080139483A1 (en) * 2006-12-12 2008-06-12 Gorczynski Richard J Drug combination for hypertensive disorders
CN103476410B (zh) * 2011-01-11 2020-02-21 戴麦里克斯生物科学有限公司 联合疗法
CN107405406A (zh) 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
WO2019183513A1 (en) 2018-03-22 2019-09-26 University Of Iowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Also Published As

Publication number Publication date
IL297373A (en) 2022-12-01
CA3180646A1 (en) 2021-10-28
LT4138790T (lt) 2024-04-10
JP2023503178A (ja) 2023-01-26
ES2976885T3 (es) 2024-08-12
US20220202726A1 (en) 2022-06-30
US12605341B2 (en) 2026-04-21
EP4389212A3 (en) 2024-10-09
WO2021214488A1 (en) 2021-10-28
KR20230005220A (ko) 2023-01-09
JP7387903B2 (ja) 2023-11-28
EP4138790B1 (en) 2024-01-31
MX2022013070A (es) 2022-11-30
AU2021260923B2 (en) 2026-03-12
EP4138790A1 (en) 2023-03-01
JP2024020417A (ja) 2024-02-14
US20240269081A1 (en) 2024-08-15
SI4138790T1 (sl) 2024-05-31
PT4138790T (pt) 2024-04-01
EP4389212A2 (en) 2024-06-26
PL4138790T3 (pl) 2024-06-10
ZA202211460B (en) 2025-02-26
CN115697309A (zh) 2023-02-03
US11844868B2 (en) 2023-12-19
BR112022021511A2 (pt) 2023-01-24
AU2021260923A1 (en) 2022-12-08
DK4138790T3 (en) 2024-03-11
IL297373B1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
EP4256011C0 (en) COMPOSITION
GB202005911D0 (en) Composition
GB202006079D0 (en) New composition
GB202006074D0 (en) New composition
GB202005593D0 (en) New composition
GB202004460D0 (en) Herbical composition
GB202103439D0 (en) Composition
GB202018029D0 (en) Composition
GB202012895D0 (en) Composition
GB202007377D0 (en) Composition
GB202016236D0 (en) Composition
GB202006081D0 (en) New composition
GB202006093D0 (en) Composition
EP4259762C0 (en) COMPOSITION
GB202103434D0 (en) Composition
GB202000619D0 (en) Composition
EP4330363C0 (en) COMPOSITION
GB202005586D0 (en) New composition
GB202104498D0 (en) Composition
GB202014635D0 (en) Composition
GB202003550D0 (en) Composition
GB202117703D0 (en) New composition
GB202117701D0 (en) New composition
GB202108297D0 (en) New composition
GB202108282D0 (en) New composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)